FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2966761506> ?p ?o ?g. }

• W2966761506 endingPage "e15600" @default.
• W2966761506 startingPage "e15600" @default.
• W2966761506 abstract "e15600 Background: To improve chemoresistance of gemcitabine (GEM) caused by GEM-induced nuclear factor kappa B (NF- κB) activation, we have conducted combination chemotherapy of GEM with NF-κB inhibitor, nafamostat mesilate (NAM) which is commercially approved as an effective therapeutic agent for disseminated intravascular coagulation, systemic response syndrome, or pancreatitis in Japan for patients with unresectable pancreatic cancer patients through phase 1/2 study. Methods: Study treatment consists of GEM 1,000 mg/m2 on d 8, 15 and 22 plus NAM 2.4∼4.8 mg/kg on d 8, 15 and 22. NAM was administered intra-arterially by continuous regional infusion for 24 hours via an infusion port system one hour before administration of GEM. Overall survival, response rate (RECIST), serum CA19–9 and clinical benefit response (body weight, pain alleviation) were assessed. Results: Between Feb 2007 and Oct 2008, 20 patients with unresectable pancreatic cancer were included in this study. Pts characteristics: male/female: 18/2, median age 63.5 (range 38–79) yrs, median Karnofsky PS 80% (range 70–90%), stage III/IV: 8/12, serum CA19–9 4,662 U/ml (range 88–32,100), baseline visual analogue scale 0–1/2–4/5–7/8–10; 9/4/7/0, baseline analgesic consumption (morphine-equivalent, mg/day) 0/10–100/100>; 10/7/3. The combination of NAM with GEM is well tolerated and MTD has not been reached. The recommended dose was GEM 1,000 mg/m2; NAM 4.8 mg/kg. Overall survival was 8.0 (range 4.7–17) months. CR/PR/NC/PD/not evaluated; 0/3/14/2/1. Serum CA19–9 reduction rate; 89%. Three pts. could become off and 1pt. could reduce oral morphine sulfate, and 5 pts. gained weight. Conclusions: The GEM/NAM regimen is safe, and the clinical data, including overall survival and clinical benefit response, suggest that the initial clinical outcome of this trial has been encouraging. An expanded cohort of the combination chemotherapy is underway. No significant financial relationships to disclose." @default.
• W2966761506 created "2019-08-13" @default.
• W2966761506 creator A5007412916 @default.
• W2966761506 creator A5014949040 @default.
• W2966761506 creator A5034172002 @default.
• W2966761506 creator A5049959626 @default.
• W2966761506 creator A5056802554 @default.
• W2966761506 creator A5057400638 @default.
• W2966761506 creator A5075524860 @default.
• W2966761506 creator A5089649906 @default.
• W2966761506 date "2009-05-20" @default.
• W2966761506 modified "2023-10-16" @default.
• W2966761506 title "A pilot phase I/II study of combination chemotherapy with nafamostat mesilate and gemcitabine for unresectable pancreatic cancer" @default.
• W2966761506 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e15600" @default.
• W2966761506 hasPublicationYear "2009" @default.
• W2966761506 type Work @default.
• W2966761506 sameAs 2966761506 @default.
• W2966761506 citedByCount "0" @default.
• W2966761506 crossrefType "journal-article" @default.
• W2966761506 hasAuthorship W2966761506A5007412916 @default.
• W2966761506 hasAuthorship W2966761506A5014949040 @default.
• W2966761506 hasAuthorship W2966761506A5034172002 @default.
• W2966761506 hasAuthorship W2966761506A5049959626 @default.
• W2966761506 hasAuthorship W2966761506A5056802554 @default.
• W2966761506 hasAuthorship W2966761506A5057400638 @default.
• W2966761506 hasAuthorship W2966761506A5075524860 @default.
• W2966761506 hasAuthorship W2966761506A5089649906 @default.
• W2966761506 hasConcept C121608353 @default.
• W2966761506 hasConcept C126322002 @default.
• W2966761506 hasConcept C141071460 @default.
• W2966761506 hasConcept C2776670229 @default.
• W2966761506 hasConcept C2776694085 @default.
• W2966761506 hasConcept C2780210213 @default.
• W2966761506 hasConcept C2780258809 @default.
• W2966761506 hasConcept C31760486 @default.
• W2966761506 hasConcept C71924100 @default.
• W2966761506 hasConcept C90924648 @default.
• W2966761506 hasConceptScore W2966761506C121608353 @default.
• W2966761506 hasConceptScore W2966761506C126322002 @default.
• W2966761506 hasConceptScore W2966761506C141071460 @default.
• W2966761506 hasConceptScore W2966761506C2776670229 @default.
• W2966761506 hasConceptScore W2966761506C2776694085 @default.
• W2966761506 hasConceptScore W2966761506C2780210213 @default.
• W2966761506 hasConceptScore W2966761506C2780258809 @default.
• W2966761506 hasConceptScore W2966761506C31760486 @default.
• W2966761506 hasConceptScore W2966761506C71924100 @default.
• W2966761506 hasConceptScore W2966761506C90924648 @default.
• W2966761506 hasIssue "15_suppl" @default.
• W2966761506 hasLocation W29667615061 @default.
• W2966761506 hasOpenAccess W2966761506 @default.
• W2966761506 hasPrimaryLocation W29667615061 @default.
• W2966761506 hasRelatedWork W1971611596 @default.
• W2966761506 hasRelatedWork W2082064396 @default.
• W2966761506 hasRelatedWork W2117077603 @default.
• W2966761506 hasRelatedWork W2319496893 @default.
• W2966761506 hasRelatedWork W2349340765 @default.
• W2966761506 hasRelatedWork W2365966720 @default.
• W2966761506 hasRelatedWork W2366580278 @default.
• W2966761506 hasRelatedWork W2370585970 @default.
• W2966761506 hasRelatedWork W2376347278 @default.
• W2966761506 hasRelatedWork W3032598722 @default.
• W2966761506 hasVolume "27" @default.
• W2966761506 isParatext "false" @default.
• W2966761506 isRetracted "false" @default.
• W2966761506 magId "2966761506" @default.
• W2966761506 workType "article" @default.